Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nicholas A. Anagnostou is active.

Publication


Featured researches published by Nicholas A. Anagnostou.


Science Translational Medicine | 2012

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.

Stefano Colloca; E. Barnes; Antonella Folgori; Ammendola; Stefania Capone; Cirillo A; Loredana Siani; M. Naddeo; Fabiana Grazioli; Maria Luisa Esposito; Ambrosio M; Sparacino A; Bartiromo M; Meola A; Smith K; Ayako Kurioka; Geraldine A. O'Hara; Katie Ewer; Nicholas A. Anagnostou; Carly M. Bliss; Adrian V. S. Hill; Cinzia Traboni; Paul Klenerman; Riccardo Cortese; Alfredo Nicosia

Simian adenoviruses screened from wild-derived candidates can prime T cell responses in man and may serve as new vaccine vector candidates. Deepening the Talent Pool Whether you’re talking about drafting for a professional sports team or hiring new lab staff, increasing the number of candidates improves your chances of the truly exceptional find. When it comes to vaccine vectors, the pool of human adenovirus candidates has been quite shallow. Although certain vectors are highly immunogenic in animal models, they can be neutralized by preexisting antibodies in humans. Yet, Colloca et al. show that viruses that are more rare in humans and are thus less likely to be neutralized are not as immunogenic. Therefore, the authors deepened the vector pool by isolating more than 1000 adenovirus strains from chimpanzees. They identified vectors that grew in human cells and were not neutralized by human sera and prevented them from replicating. As with human adenoviral vectors, different simian vectors induced either more or less potent immune responses in mice. The more potent of these vectors were also immunogenic in humans. These chimp adenoviral vectors provide such embarrassment of riches that different vectors could be used for each vaccine target, lowering the chances of subsequent cross-reactive neutralization. Thus, these vectors serve as prime candidates for future vaccine development. Replication-defective adenovirus vectors based on human serotype 5 (Ad5) induce protective immune responses against diverse pathogens and cancer in animal models, as well as elicit robust and sustained cellular immunity in humans. However, most humans have neutralizing antibodies to Ad5, which can impair the immunological potency of such vaccines. Here, we show that rare serotypes of human adenoviruses, which should not be neutralized in most humans, are far less potent as vaccine vectors than Ad5 in mice and nonhuman primates, casting doubt on their potential efficacy in humans. To identify novel vaccine carriers suitable for vaccine delivery in humans, we isolated and sequenced more than 1000 adenovirus strains from chimpanzees (ChAd). Replication-defective vectors were generated from a subset of these ChAd serotypes and screened to determine whether they were neutralized by human sera and able to grow in human cell lines. We then ranked these ChAd vectors by immunological potency and found up to a thousandfold variation in potency for CD8+ T cell induction in mice. These ChAd vectors were safe and immunologically potent in phase 1 clinical trials, thereby validating our screening approach. These data suggest that the ChAd vectors developed here represent a large collection of non–cross-reactive, potent vectors that may be exploited for the development of new vaccines.


Molecular Therapy | 2012

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans

Susanne H. Sheehy; Christopher J. A. Duncan; Sean C. Elias; Prateek Choudhary; Sumi Biswas; Fenella D. Halstead; Katharine A. Collins; Nick J. Edwards; Alexander D. Douglas; Nicholas A. Anagnostou; Katie Ewer; Tom Havelock; Tabitha Mahungu; Carly M. Bliss; Kazutoyo Miura; Ian D. Poulton; Patrick J. Lillie; Richard D. Antrobus; Eleanor Berrie; Sarah Moyle; Katherine Gantlett; Stefano Colloca; Riccardo Cortese; Carole A. Long; Robert E. Sinden; Sarah C. Gilbert; Alison M. Lawrie; Tom Doherty; Saul N. Faust; Alfredo Nicosia

The induction of cellular immunity, in conjunction with antibodies, may be essential for vaccines to protect against blood-stage infection with the human malaria parasite Plasmodium falciparum. We have shown that prime-boost delivery of P. falciparum blood-stage antigens by chimpanzee adenovirus 63 (ChAd63) followed by the attenuated orthopoxvirus MVA is safe and immunogenic in healthy adults. Here, we report on vaccine efficacy against controlled human malaria infection delivered by mosquito bites. The blood-stage malaria vaccines were administered alone, or together (MSP1+AMA1), or with a pre-erythrocytic malaria vaccine candidate (MSP1+ME-TRAP). In this first human use of coadministered ChAd63-MVA regimes, we demonstrate immune interference whereby responses against merozoite surface protein 1 (MSP1) are dominant over apical membrane antigen 1 (AMA1) and ME-TRAP. We also show that induction of strong cellular immunity against MSP1 and AMA1 is safe, but does not impact on parasite growth rates in the blood. In a subset of vaccinated volunteers, a delay in time to diagnosis was observed and sterilizing protection was observed in one volunteer coimmunized with MSP1+AMA1-results consistent with vaccine-induced pre-erythrocytic, rather than blood-stage, immunity. These data call into question the utility of T cell-inducing blood-stage malaria vaccines and suggest that the focus should remain on high-titer antibody induction against susceptible antigen targets.


The Journal of Infectious Diseases | 2015

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.

Susanne H. Hodgson; Katie Ewer; Carly M. Bliss; Nick J. Edwards; Thomas Rampling; Nicholas A. Anagnostou; Eoghan de Barra; Tom Havelock; Georgina Bowyer; Ian D. Poulton; Simone C. de Cassan; Rhea J. Longley; Joseph J. Illingworth; Alexander D. Douglas; Pooja B. Mange; Katharine A. Collins; Rachel Roberts; Stephen Gerry; Eleanor Berrie; Sarah Moyle; Stefano Colloca; Riccardo Cortese; Robert E. Sinden; Sarah C. Gilbert; Philip Bejon; Alison M. Lawrie; Alfredo Nicosia; Saul N. Faust; Adrian V. S. Hill

Background. Circumsporozoite protein (CS) is the antigenic target for RTS,S, the most advanced malaria vaccine to date. Heterologous prime-boost with the viral vectors simian adenovirus 63 (ChAd63)-modified vaccinia virus Ankara (MVA) is the most potent inducer of T-cells in humans, demonstrating significant efficacy when expressing the preerythrocytic antigen insert multiple epitope–thrombospondin-related adhesion protein (ME-TRAP). We hypothesized that ChAd63-MVA containing CS may result in a significant clinical protective efficacy. Methods. We conducted an open-label, 2-site, partially randomized Plasmodium falciparum sporozoite controlled human malaria infection (CHMI) study to compare the clinical efficacy of ChAd63-MVA CS with ChAd63-MVA ME-TRAP. Results. One of 15 vaccinees (7%) receiving ChAd63-MVA CS and 2 of 15 (13%) receiving ChAd63-MVA ME-TRAP achieved sterile protection after CHMI. Three of 15 vaccinees (20%) receiving ChAd63-MVA CS and 5 of 15 (33%) receiving ChAd63-MVA ME-TRAP demonstrated a delay in time to treatment, compared with unvaccinated controls. In quantitative polymerase chain reaction analyses, ChAd63-MVA CS was estimated to reduce the liver parasite burden by 69%–79%, compared with 79%–84% for ChAd63-MVA ME-TRAP. Conclusions. ChAd63-MVA CS does reduce the liver parasite burden, but ChAd63-MVA ME-TRAP remains the most promising antigenic insert for a vectored liver-stage vaccine. Detailed analyses of parasite kinetics may allow detection of smaller but biologically important differences in vaccine efficacy that can influence future vaccine development. Clinical Trials Registration. NCT01623557.


PLOS ONE | 2013

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME- TRAP, in Healthy Gambian and Kenyan Adults

Caroline Ogwang; Muhammed O. Afolabi; Domtila Kimani; Ya Jankey Jagne; Susanne H. Sheehy; Carly M. Bliss; Christopher J. A. Duncan; Katharine A. Collins; Miguel G Knight; Eva Kimani; Nicholas A. Anagnostou; Eleanor Berrie; Sarah Moyle; Sarah C. Gilbert; Alexandra J. Spencer; Peninah Soipei; Jenny Mueller; Joseph Okebe; Stefano Colloca; Riccardo Cortese; Nicola K. Viebig; Rachel Roberts; Katherine Gantlett; Alison M. Lawrie; Alfredo Nicosia; Egeruan B. Imoukhuede; Philip Bejon; Britta C. Urban; Katie L. Flanagan; Katie Ewer

Background Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria naïve adults following controlled human malaria infection (CHMI). Methodology We conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns. Results ChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC). Conclusions ChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted. Trial Registration Pactr.org PACTR2010020001771828 Pactr.org PACTR201008000221638 ClinicalTrials.gov NCT01373879 NCT01373879 ClinicalTrials.gov NCT01379430 NCT01379430


PLOS ONE | 2013

Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe

Susanne H. Sheehy; Alexandra J. Spencer; Alexander D. Douglas; B. Kim Lee Sim; Rhea J. Longley; Nick J. Edwards; Ian D. Poulton; Domtila Kimani; Andrew R. Williams; Nicholas A. Anagnostou; Rachel Roberts; Simon Kerridge; Merryn Voysey; Eric R. James; Peter F. Billingsley; Anusha Gunasekera; Alison M. Lawrie; Stephen L. Hoffman; Adrian V. S. Hill

Background Controlled human malaria infection (CHMI) studies have become a routine tool to evaluate efficacy of candidate anti-malarial drugs and vaccines. To date, CHMI trials have mostly been conducted using the bite of infected mosquitoes, restricting the number of trial sites that can perform CHMI studies. Aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) provide a potentially more accurate, reproducible and practical alternative, allowing a known number of sporozoites to be administered simply by injection. Methodology We sought to assess the infectivity of PfSPZ Challenge administered in different dosing regimens to malaria-naive healthy adults (n = 18). Six participants received 2,500 sporozoites intradermally (ID), six received 2,500 sporozoites intramuscularly (IM) and six received 25,000 sporozoites IM. Findings Five out of six participants receiving 2,500 sporozoites ID, 3/6 participants receiving 2,500 sporozoites IM and 6/6 participants receiving 25,000 sporozoites IM were successfully infected. The median time to diagnosis was 13.2, 17.8 and 12.7 days for 2,500 sporozoites ID, 2,500 sporozoites IM and 25,000 sporozoites IM respectively (Kaplan Meier method; p = 0.024 log rank test). Conclusions 2,500 sporozoites ID and 25,000 sporozoites IM have similar infectivities. Given the dose response in infectivity seen with IM administration, further work should evaluate increasing doses of PfSPZ Challenge IM to identify a dosing regimen that reliably infects 100% of participants. Trial Registration ClinicalTrials.gov NCT01465048


Molecular Therapy | 2014

Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations

Domtila Kimani; Ya Jankey Jagne; Momodou Cox; Eva Kimani; Carly M. Bliss; Evelyn Gitau; Caroline Ogwang; Muhammed O. Afolabi; Georgina Bowyer; Katharine A. Collins; Nick J. Edwards; Susanne H. Hodgson; Christopher J. A. Duncan; Alexandra J. Spencer; Miguel G Knight; Abdoulie Drammeh; Nicholas A. Anagnostou; Eleanor Berrie; Sarah Moyle; Sarah C. Gilbert; Peninah Soipei; Joseph Okebe; Stefano Colloca; Riccardo Cortese; Nicola K. Viebig; Rachel Roberts; Alison M. Lawrie; Alfredo Nicosia; Egeruan B. Imoukhuede; Philip Bejon

To induce a deployable level of efficacy, a successful malaria vaccine would likely benefit from both potent cellular and humoral immunity. These requirements are met by a heterologous prime-boost immunization strategy employing a chimpanzee adenovirus vector followed by modified vaccinia Ankara (MVA), both encoding the pre-erythrocytic malaria antigen ME-thrombospondin-related adhesive protein (TRAP), with high immunogenicity and significant efficacy in UK adults. We undertook two phase 1b open-label studies in adults in Kenya and The Gambia in areas of similar seasonal malaria transmission dynamics and have previously reported safety and basic immunogenicity data. We now report flow cytometry and additional interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) data characterizing pre-existing and induced cellular immunity as well as anti-TRAP IgG responses. T-cell responses induced by vaccination averaged 1,254 spot-forming cells (SFC) per million peripheral blood mononuclear cells (PBMC) across both trials and flow cytometry revealed cytokine production from both CD4(+) and CD8(+) T cells with the frequency of CD8(+) IFN-γ-secreting monofunctional T cells (previously shown to associate with vaccine efficacy) particularly high in Kenyan adults. Immunization with ChAd63 and MVA ME-TRAP induced strong cellular and humoral immune responses in adults living in two malaria-endemic regions of Africa. This prime-boost approach targeting the pre-erythrocytic stage of the malaria life-cycle is now being assessed for efficacy in a target population.


The Journal of Infectious Diseases | 2013

Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection

Alexander D. Douglas; Nick J. Edwards; Christopher J. A. Duncan; Fiona M. Thompson; Susanne H. Sheehy; Geraldine A. O'Hara; Nicholas A. Anagnostou; Michael Walther; Daniel P. Webster; Susanna Dunachie; David Porter; Laura Andrews; Sarah C. Gilbert; Simon J. Draper; Adrian V. S. Hill; Philip Bejon

Controlled human malaria infection is used to measure efficacy of candidate malaria vaccines before field studies are undertaken. Mathematical modeling using data from quantitative polymerase chain reaction (qPCR) parasitemia monitoring can discriminate between vaccine effects on the parasites liver and blood stages. Uncertainty regarding the most appropriate modeling method hinders interpretation of such trials. We used qPCR data from 267 Plasmodium falciparum infections to compare linear, sine-wave, and normal-cumulative-density-function models. We find that the parameters estimated by these models are closely correlated, and their predictive accuracy for omitted data points was similar. We propose that future studies include the linear model.


Molecular Therapy | 2016

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

Muhammed O. Afolabi; Alfred B. Tiono; Uche J. Adetifa; Jean Baptiste Yaro; Abdoulie Drammeh; Issa Nebie; Carly M. Bliss; Susanne H. Hodgson; Nicholas A. Anagnostou; Guillaume S. Sanou; Ya Jankey Jagne; Oumarou Ouédraogo; Casimir Tamara; Nicolas Ouedraogo; Mirielle Ouedraogo; Jainaba Njie-Jobe; Amidou Diarra; Christopher J. A. Duncan; Riccardo Cortese; Alfredo Nicosia; Rachel Roberts; Nicola K. Viebig; Odile Leroy; Alison M. Lawrie; Katie L. Flanagan; Beate Kampman; Philip Bejon; Egeruan B. Imoukhuede; Katie Ewer; Adrian V. S. Hill

Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2–6 years old in The Gambia; 5–17 months old in Burkina Faso; 5–12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.


PLOS ONE | 2016

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal

Victorine Mensah; Aly Gueye; Magatte Ndiaye; Nick J. Edwards; Danny Wright; Nicholas A. Anagnostou; Massamba Syll; Amy Ndaw; Annie Abiola; Carly M. Bliss; Jules-Francois Gomis; Ines Petersen; Caroline Ogwang; Tandakha Ndiaye Dieye; Nicola K. Viebig; Alison M. Lawrie; Rachel Roberts; Alfredo Nicosia; Babacar Faye; Oumar Gaye; Odile Leroy; Egeruan B. Imoukhuede; Katie Ewer; Philip Bejon; Adrian V. S. Hill; Badara Cisse

Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of control measures. If the goal of elimination is to be achieved, additional control measures including an effective and durable vaccine will be required. Studies utilising the prime-boost approach to deliver viral vectors encoding the pre-erythrocytic antigen ME-TRAP (multiple epitope thrombospondin-related adhesion protein) have shown promising safety, immunogenicity and efficacy in sporozoite challenge studies. More recently, a study in Kenyan adults, similar to that reported here, showed substantial efficacy against P. falciparum infection. One hundred and twenty healthy male volunteers, living in a malaria endemic area of Senegal were randomised to receive either the Chimpanzee adenovirus (ChAd63) ME-TRAP as prime vaccination, followed eight weeks later by modified vaccinia Ankara (MVA) also encoding ME-TRAP as booster, or two doses of anti-rabies vaccine as a comparator. Prior to follow-up, antimalarials were administered to clear parasitaemia and then participants were monitored by PCR for malaria infection for eight weeks. The primary endpoint was time-to-infection with P. falciparum malaria, determined by two consecutive positive PCR results. Secondary endpoints included adverse event reporting, measures of cellular and humoral immunogenicity and a meta-analysis of combined vaccine efficacy with the parallel study in Kenyan adults.We show that this pre-erythrocytic malaria vaccine is safe and induces significant immunogenicity, with a peak T-cell response at seven days after boosting of 932 Spot Forming Cells (SFC)/106 Peripheral Blood Mononuclear Cells(PBMC) compared to 57 SFC/ 106 PBMCs in the control group. However, a vaccine efficacy was not observed: 12 of 57 ME-TRAP vaccinees became PCR positive during the intensive monitoring period as compared to 13 of the 58 controls (P = 0.80). This trial confirms that vaccine efficacy against malaria infection in adults may be rapidly assessed using this efficient and cost-effective clinical trial design. Further efficacy evaluation of this vectored candidate vaccine approach in other malaria transmission settings and age-de-escalation into the main target age groups for a malaria vaccine is in progress.


Molecular Therapy | 2017

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

Carly M. Bliss; Abdoulie Drammeh; Georgina Bowyer; Guillaume S. Sanou; Ya Jankey Jagne; Oumarou Ouédraogo; Nick J. Edwards; Casimir Tarama; Nicolas Ouedraogo; Mireille Ouedraogo; Jainaba Njie-Jobe; Amidou Diarra; Muhammed O. Afolabi; Alfred B. Tiono; Jean Baptiste Yaro; Uche J. Adetifa; Susanne H. Hodgson; Nicholas A. Anagnostou; Rachel Roberts; Christopher J. A. Duncan; Riccardo Cortese; Nicola K. Viebig; Odile Leroy; Alison M. Lawrie; Katie L. Flanagan; Beate Kampmann; Egeruan B. Imoukhuede; Sodiomon B. Sirima; Kalifa Bojang; Adrian V. S. Hill

Heterologous prime-boosting with viral vectors encoding the pre-erythrocytic antigen thrombospondin-related adhesion protein fused to a multiple epitope string (ME-TRAP) induces CD8+ T cell-mediated immunity to malaria sporozoite challenge in European malaria-naive and Kenyan semi-immune adults. This approach has yet to be evaluated in children and infants. We assessed this vaccine strategy among 138 Gambian and Burkinabe children in four cohorts: 2- to 6-year olds in The Gambia, 5- to 17-month-olds in Burkina Faso, and 5- to 12-month-olds and 10-week-olds in The Gambia. We assessed induction of cellular immunity, taking into account the distinctive hematological status of young infants, and characterized the antibody response to vaccination. T cell responses peaked 7 days after boosting with modified vaccinia virus Ankara (MVA), with highest responses in infants aged 10 weeks at priming. Incorporating lymphocyte count into the calculation of T cell responses facilitated a more physiologically relevant comparison of cellular immunity across different age groups. Both CD8+ and CD4+ T cells secreted cytokines. Induced antibodies were up to 20-fold higher in all groups compared with Gambian and United Kingdom (UK) adults, with comparable or higher avidity. This immunization regimen elicited strong immune responses, particularly in young infants, supporting future evaluation of efficacy in this key target age group for a malaria vaccine.

Collaboration


Dive into the Nicholas A. Anagnostou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alfredo Nicosia

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge